Menu
MorphoSys US

It’s our mission to deliver innovative therapies to improve the lives of patients impacted by cancer and autoimmune diseases.

Visit our Online Magazine

MorphoSys' mission

MorphoSys mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

Latest
news

11/05/2021
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND...
Read Media Release
05/05/2021
MorphoSys AG Reports First Quarter 2021 Results
Read Media Release
28/04/2021
Invitation to MorphoSys' First Quarter Results Conference Call on May...
Read Media Release
19/04/2021
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study...
Read Media Release
15/03/2021
MorphoSys AG Presents Results for Full Year 2020
Read Media Release
09/03/2021
Invitation to MorphoSys' Full Year Results 2020 Conference Call on...
Read Media Release
02/03/2021
MorphoSys's Licensing Partner GSK Shared Preliminary Results From...
Read Media Release
01/03/2021
Ad hoc: MorphoSys AG preliminary results for the fiscal year 2020...
Read Media Release
25/01/2021
MorphoSys AG: MorphoSys and I-Mab Announce First Patient Dosed in U.S....
Read Media Release
12/01/2021
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug...
Read Media Release

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

Do you wish to proceed?

Yes No

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

Do you wish to proceed?

Yes No

You are leaving morphosys.com and will be transferred to the Monjuvi(®) US website which is intended for US residents.

Do you wish to proceed?

Yes No